MX6A Stock Overview An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Grand Pharmaceutical Group Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Grand Pharmaceutical Group Historical stock prices Current Share Price HK$0.54 52 Week High HK$0.62 52 Week Low HK$0.38 Beta 0.75 1 Month Change -0.92% 3 Month Change -6.09% 1 Year Change n/a 3 Year Change -21.17% 5 Year Change n/a Change since IPO -23.73%
Recent News & Updates
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27 See more updates
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27
New minor risk - Share price stability Sep 19
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 29
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Executive Chairman recently bought €44k worth of stock Apr 26
Dividend of HK$0.26 announced Mar 25 Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022) Mar 20
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Less than half of directors are independent Feb 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Less than half of directors are independent Dec 16
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 13
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.8% yield Jun 02
Less than half of directors are independent May 18 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Less than half of directors are independent Nov 16
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021) Sep 29
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
Less than half of directors are independent Aug 23
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Less than half of directors are independent Jul 07
Executive Director recently bought €64k worth of stock Jun 10
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Less than half of directors are independent May 02
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Now 21% undervalued after recent price drop Feb 23
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 12
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Less than half of directors are independent Jul 27 Shareholder Returns MX6A DE Pharmaceuticals DE Market 7D -2.7% 2.2% 0.7% 1Y n/a -16.8% 8.4%
See full shareholder returns
Return vs Market: Insufficient data to determine how MX6A performed against the German Market .
Price Volatility Is MX6A's price volatile compared to industry and market? MX6A volatility MX6A Average Weekly Movement 11.5% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MX6A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MX6A's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products.
Show more Grand Pharmaceutical Group Limited Fundamentals Summary How do Grand Pharmaceutical Group's earnings and revenue compare to its market cap? MX6A fundamental statistics Market cap €2.02b Earnings (TTM ) €301.76m Revenue (TTM ) €1.33b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MX6A income statement (TTM ) Revenue HK$10.59b Cost of Revenue HK$4.34b Gross Profit HK$6.25b Other Expenses HK$3.84b Earnings HK$2.41b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.69 Gross Margin 59.00% Net Profit Margin 22.75% Debt/Equity Ratio 28.1%
How did MX6A perform over the long term?
See historical performance and comparison Dividends
5.7% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 12:15 End of Day Share Price 2025/01/02 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Grand Pharmaceutical Group Limited is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
Show 4 more analysts 